Skip to content
10-Q

Quarterly Report

Lazuriton Nano Biotechnology (U.S.A.) Inc.

0001640334-21-002186

← back to feed
Filed
Sep 14, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Sep 30, 2021 100M sh
Cash And Equivalents Q3 2020 · Sep 30, 2020 $1.35K
Cash And Equivalents Q3 2020 · Dec 31, 2019 $1.35K
Cash And Equivalents Q3 2020 · Sep 30, 2019 $1.35K
Cash And Equivalents Q3 2020 · Dec 31, 2018 $1.2K
Current Liabilities Q3 2020 · Sep 30, 2020 $302.18K
Current Liabilities Q3 2020 · Dec 31, 2019 $269.88K
Total Liabilities Q3 2020 · Sep 30, 2020 $302.18K
Total Liabilities Q3 2020 · Dec 31, 2019 $269.88K
Current Assets Q3 2020 · Sep 30, 2020 $1.35K
Current Assets Q3 2020 · Dec 31, 2019 $1.35K
Total Assets Q3 2020 · Sep 30, 2020 $1.35K
Total Assets Q3 2020 · Dec 31, 2019 $1.35K
Operating Cash Flow Q3 2020 · Sep 30, 2019 $150
Stockholders Equity Q3 2020 · Sep 30, 2019 −$249.09K
Stockholders Equity Q3 2020 · Jun 30, 2019 −$231.84K
Stockholders Equity Q3 2020 · Mar 31, 2019 −$217.37K
Stockholders Equity Q3 2020 · Dec 31, 2018 −$196.76K
Sga Expense Q3 2020 · Sep 30, 2019 $17.25K
Sga Expense Q3 2020 · Sep 30, 2019 $52.33K
Net Income Q3 2020 · Sep 30, 2019 −$17.25K
Net Income Q3 2020 · Sep 30, 2019 −$52.33K
Net Income Q3 2020 · Jun 30, 2019 −$14.47K
Net Income Q3 2020 · Mar 31, 2019 −$20.61K
Operating Income Q3 2020 · Sep 30, 2019 −$17.25K
Operating Income Q3 2020 · Sep 30, 2019 −$52.33K
Revenue Q3 2020 · Sep 30, 2019 $0
Revenue Q3 2020 · Sep 30, 2019 $0